# KarMMa-7 (NCT04855136)

> Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04855136
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: BB2121; CC-220; BMS-986405
- Enrollment: 21
- Primary outcome: Does Limiting Toxicity (DLT) rates _Phase 1
- Primary outcome: Complete Response Rate (CRR)_ Phase 2

## Indexed commentary on KarMMa-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=karmma-7-nct04855136